HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.

Abstract
Anti-Hu paraneoplastic syndromes are usually associated with an underlying neoplasia, although a few patients who are anti-Hu-positive never develop cancer after long-term follow-up. Tumour therapy remains the mainstay of therapeutic options, and early immune therapy in parallel is advisable. When no tumour is found, immunologically-based therapies are nowadays the only options. Recent studies have shown rituximab associated with the tumour therapy to be effective for some patients with anti-Hu paraneoplastic syndrome. We report a case of a patient with anti-Hu antibodies-associated sensory neuronopathy and gastric pseudo-obstruction without an underlying neoplasia four years after the first manifestation who has achieved sustained improvement for two years after treatment with rituximab. This case report supports the effectiveness of rituximab in these syndromes, even for cases where no underlying neoplasia is demonstrated. Further studies are warranted in order to confirm these preliminary data.
AuthorsFrancisco Coret, Isabel Bosca, Loren Fratalia, Jaume Perez-Griera, Ana Pascual, Bonaventura Casanova
JournalJournal of neuro-oncology (J Neurooncol) Vol. 93 Issue 3 Pg. 421-3 (Jul 2009) ISSN: 1573-7373 [Electronic] United States
PMID19139820 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Autoantibodies
  • ELAV Proteins
  • Rituximab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (therapeutic use)
  • Autoantibodies (blood)
  • ELAV Proteins (immunology)
  • Female
  • Humans
  • Intestinal Pseudo-Obstruction (etiology)
  • Middle Aged
  • Paraneoplastic Syndromes, Nervous System (complications, drug therapy)
  • Polyradiculoneuropathy (etiology)
  • Remission Induction
  • Rituximab
  • Stomach Diseases (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: